Tracing ASCO | Professor Yijun Shen: China-Developed Immunotherapy–ADC Combinations Take the ASCO Stage, Reshaping the Future of Genitourinary Cancer Treatment
The combination of immune checkpoint inhibitors and antibody-drug conjugates (ADCs) is rapidly expanding from the first-line treatment of advanced disease into the perioperative setting, fundamentally reshaping the treatment landscape of urothelial carcinoma (UC). As global research momentum continues to accelerate, Chinese-developed immunotherapy–ADC combinations are emerging as important contributors to this evolving field.









